PulmOne

PulmOne Overview

PulmOne develops patient-friendly, hassle-free, and budget-conscious devices designed to accurately inform clinical decision making throughout the diagnosis, treatment, and monitoring of respiratory diseases. The company's MiniBox is a system for measuring lung volume and spirometry. It is a desktop device designed to provide an accurate assessment of lung volume based on normal tidal breathing and a short measurement time. The system does not rely on a plethysmograph or external gas source. PulmOne's MiniBox+ adds to the spirometry and LVM tests with a diffusing capacity (DLCO) module, providing a complete solution. The company has received FDA 510k clearance and a CE mark for its first product and started sales in several locations.

Cumulative Funding Raised Over Time ($)

Latest News

Feb 21, 2022 · www.timesofisrael.com

growth-positive

Portable lung tests help patients breathe easier - Sponsored Content The Times of Israel

PulmOne, an Israeli startup, has developed MiniBox+, a compact device that allows pulmonary tests to be performed in clinics everywhere, reducing costs and speeding up diagnosis of lung diseases. The device, which has received FDA clearance, uses patented algorithms, machine-based learning, and an internal gasless measurement system to replace the traditional large, cumbersome equipment. PulmOne has signed agreements with a top US healthcare company and a leading medical technology distributor in China, and its revenues have more than doubled from 2020 to 2021. The company is currently raising funds on the OurCrowd platform.

CustomersPartnersInvestmentExpand

Dec 14, 2021 · www.calcalist.co.il

growth-positive

קרן רגנאר תשקיע 6.5 מיליון שקל בחברת המכשור הרפואי פאלם וואן כלכליסט

Regenar Fund is investing 6.5 million shekels in PalmOne, a company that develops and markets advanced medical equipment for lung function tests. PalmOne was aiming for an IPO at a value of $120 million, but business losses led to indications that it would not be able to raise the amount and the IPO was postponed. Instead, the company raised funds from Regenar at a value to be determined in the future. PalmOne has approval to market its products in the European Union since 2013, and from the American FDA since 2014.

Investment

Jun 9, 2021 · www.themarker.com

growth-positive

פאלם וואן רוצה להנפיק בתל אביב לפי שווי של 120 מיליון דולר

Israeli medical equipment company Pulm One has received FDA and European Union approval to market its flagship device for lung function testing. The company has begun sales, including to medical centers in the US. The medical equipment market for lungs and breathing has seen increased demand due to the coronavirus, growing by 261% between 2019 and 2020. Pulm One is interested in issuing on the Tel Aviv Stock Exchange at a value of $120 million (420 million shekels).

Public Trading

Nov 7, 2019 · www.prnewswire.com

growth-positive

PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System

PulmOne USA Inc. has partnered with Circassia Pharmaceuticals to integrate the NIOX VERO fractional exhaled nitric oxide (FeNO) airway inflammation measurement system into PulmOnes MiniBox+. The integrated system will be offered to existing and new customers. The MiniBox+ is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients. The integration of the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat a wider range of respiratory disorders.

PartnersCustomers

Funding

Team Members

6

Employees: 51-200

Web & Social Links

Locations

Ha-Melakha Street 14, Ra'anana, Israel

444 Madison Avenue, New York, NY, USA

Photos & Videos

3 item(s)

PulmOne Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info